Yann Barguil

Yann Barguil

Auto-generated profile, based on publicly available information

Yann Barguil

Laboratoire de biochimie-toxicologie, Centre hospitalier territorial Gaston-Bourret, Nouméa, Nouvelle-Calédonie

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SRStefan Russmann
Stefan Russmann
YBYann Barguil
Yann Barguil
PCPierre Cabalion
Pierre Cabalion
MKMarina Kritsanida
Marina Kritsanida
DDDaniel Duhet
Daniel Duhet
BLBernhard H Lauterburg
Bernhard H Lauterburg
Traditional aqueous kava extracts were the most probable cause of hepatitis in two patients presenting with markedly elevated transaminases and hyperbilirubinaemia. A consequent survey of 27 heavy kava drinkers in New Caledonia showed elevated gamma glutamyl transferase in 23/27 and minimally elevated transaminases in 8/27. We conclude that not only commercially available, but also traditionally prepared kava extracts may rarely cause liver injury. The increased activity of gamma glutamyl transferase in heavy kava consumers in the presence of normal or minimally elevated transaminases is probably not a sign of liver injury, but rather reflects an induction of CYP450 enzymes.

1 September 2006 in Journal of Analytical Toxicology
Verified
Journal Article
Open access
PDF file
PKPascal Kintz
Pascal Kintz
MVMarion Villain
Marion Villain
YBYann Bargul
Yann Bargul
JCJean-Yves Charlot
Jean-Yves Charlot
VCVincent Cirimele
Vincent Cirimele
Datura inoxia belongs to the family of Solanaceae. This is a very common plant in New Caledonia that contains two main toxic alkaloids, l-atropine and l-scopolamine. In this study, we report the case of a 20-year-old male admitted to an Emergency Unit after consumption of 6 dried flowers in hot water for hallucinations, mydriasis, and agitation associated with tachycardia and increase of systolic blood pressure to 180. Full recovery was observed after one week. Three weeks later, a lock of about 80 hairs (200 mg) was collected from the subject in vertex posterior with scissors to be tested for both atropine and scopolamine. After decontamination with dichloromethane, a strand of hair was segmented into three parts, cut into small segments (< 1 mm), incubated overnight in 1 mL pH 8.4 phosphate buffer in the presence of 2.5 ng atropine-d3, the internal standard, then extracted with 5 mL dichloromethane/isopropanol/n-heptane (50:17:33). The residue was reconstituted in 100 µL of methanol, from which 10 µL was injected into an XTerra MS C18 column (100 × 2.1 mm, 3.5 µm) eluted with a gradient of acetonitrile and formate buffer delivered at a flow rate of 0.2 mL/min. A Quattro Micro triple-quadrupole mass spectrometer (MS) was used for analyses. Ionization was achieved using electrospray in the positive ionization mode. For each compound, detection was related to two daughter ions (atropine: m/z 290.2 to 124.0 and 92.9; atropine-d3: m/z 293.1 to 127.0 and 92.9; scopolamine: m/z 304.1 to 138.0 and 156.0). Although atropine was never detected (limit of detection = 2 pg/mg), scopolamine was identified in the three segments, in the range 14 to 48 pg/mg. The absence of atropine in hair is consistent with its very low dosage in the flower of Datura inoxia. Hair segmentation indicated that the subject was previously exposed on several occasions to the plant. Liquid chromatography-tandem MS appears to be a necessity for testing tropane alkaloids of the Datura group, given the low concentrations to be measured.

21 November 2014 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MMM. Mikulski
M. Mikulski
PBP. Boisier
P. Boisier
FLF. Lacassin
F. Lacassin
MSM.-E. Soupé-Gilbert
M.-E. Soupé-Gilbert
CMC. Mauron
C. Mauron
CGCyrille Goarant
Cyrille Goarant

1 May 2005 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SRS Russmann
S Russmann
BLB Lauterburg
B Lauterburg
YBY Barguil
Y Barguil
ECE Choblet
E Choblet
PCP Cabalion
P Cabalion
MWM Wenk
M Wenk

4 November 2015 in Heart
Verified
Journal Article
Open access
PDF file
MMMariana Mirabel
Mariana Mirabel
MTMuriel Tafflet
Muriel Tafflet
BNBaptiste Noël
Baptiste Noël
TPTom Parks
Tom Parks
OAOlivier Axler
Olivier Axler
XJXavier Jouven
Xavier Jouven
Objectives Rheumatic heart disease (RHD) remains the leading acquired heart disease in the young worldwide. We aimed at assessing outcomes and influencing factors in the contemporary era. Methods Hospital-based cohort in a high-income island nation where RHD remains endemic and the population is captive. All patients admitted with newly diagnosed RHD according to World Heart Federation echocardiographic criteria were enrolled (2005–2013). The incidence of major cardiovascular events (MACEs) including heart failure, peripheral embolism, stroke, heart valve intervention and cardiovascular death was calculated, and their determinants identified. Results Of the 396 patients, 43.9% were male with median age 18 years (IQR 10–40)). 127 (32.1%) patients presented with mild, 131 (33.1%) with moderate and 138 (34.8%) with severe heart valve disease. 205 (51.8%) had features of acute rheumatic fever. 106 (26.8%) presented with at least one MACE. Among the remaining 290 patients, after a median follow-up period of 4.08 (95% CI 1.84 to 6.84) years, 7 patients (2.4%) died and 62 (21.4%) had a first MACE. The annual incidence of first MACE and of heart failure were 59.05‰ (95% CI 44.35 to 73.75) and 29.06‰ (95% CI 19.29 to 38.82), respectively. The severity of RHD at diagnosis (moderate vs mild HR 3.39 (0.95 to 12.12); severe vs mild RHD HR 10.81 (3.11 to 37.62), p<0.001) and ongoing secondary prophylaxis at follow-up (HR 0.27 (0.12 to 0.63), p=0.01) were the two most influential factors associated with MACE. Conclusions Newly diagnosed RHD is associated with poor outcomes, mainly in patients with moderate or severe valve disease and no secondary prophylaxis.

1 November 2012 in Toxicon
Verified
Journal Article
Closed access
CMClaude MAILLAUD
Claude MAILLAUD
YBY. Barguil
Y. Barguil
MMM. Mikulski
M. Mikulski
MCM. Cheze
M. Cheze
CPC. Pivert
C. Pivert
FLF. Lapostolle
F. Lapostolle